In the present work, tamoxifen-derived metabolite-resistant variant MCF-7Var E was generated as a model to replicate the chemoresistant phenotype observed in patients with ER+ breast cancer, wherein tamoxifen is one of the main adjuvants used. This evidence concerns the gene ESR1 and breast carcinoma.